Vitamin D can ameliorate premature ovarian failure by inhibiting neutrophil extracellular traps: A review

Menglu Chen, Lailai Li, Yihui Chai, Yuqi Yang, Sibu Ma, Xiang Pu, Yunzhi Chen
Medicine · 2023 · vol. 102(13) , pp. e33417 · doi:10.1097/md.0000000000033417 · PMID:37000081 · PMC10063315 · W4362469169
Review OA: gold CC0 ⤵ 3 in-corpus citations
📄 Open PDF Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-10 ⓘ

This review theorizes that Vitamin D ameliorates premature ovarian failure by inhibiting neutrophil extracellular traps and intervening in inflammatory, immune, oxidative stress, and fibrotic responses.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-10-10 · read from full text ⓘ

This review examines the potential of vitamin D to ameliorate premature ovarian failure by inhibiting neutrophil extracellular traps and mitigating associated tissue damage. The authors outline how vitamin D exerts protective effects through anti-inflammatory, antioxidant, and antifibrotic mechanisms, including the suppression of pro-inflammatory cytokines, reduction of oxidative stress via the Nrf2 pathway, and inhibition of fibrosis mediated by TGF-β1 signaling. These pathways collectively help preserve ovarian follicle development and function in the context of chemotherapy-induced or idiopathic ovarian hypofunction. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

The etiology of premature ovarian failure (POF) is mainly related to inflammatory diseases, autoimmune diseases, and tumor radiotherapy and chemotherapy; however, its specific pathogenesis has not been clarified. Vitamin D (VD), a fat-soluble vitamin, is an essential steroid hormone in the human body. Neutrophil extracellular traps (NETs) are meshwork structures that are formed when neutrophils are stimulated by inflammation and other factors and are closely associated with autoimmune and inflammatory diseases. Notably, VD inhibits NET formation and intervenes in the development of POF in terms of inflammatory and immune responses, oxidative stress, and tissue fibrosis. Therefore, this study aimed to theorize the relationship between NETs, VD, and POF and provide new ideas and targets for the pathogenesis and clinical treatment of POF.
Full text 22,358 characters · extracted from pmc-nxml · 8 sections · click to expand

Section 2

Current research suggests that the pathogenesis of POF may be related to the inflammatory response, autoimmunity, oxidative stress, and tissue fibrosis caused by radiotherapy and chemotherapy. [ 4 , 5 ] Inflammation and autoimmune responses can lead to tissue damage and dysfunction. It has been shown that tumor necrosis factor α (TNF-α) binding to its receptor in the ovary could induce elevated levels of nuclear factor kappa-B (NF-κB), activate the TLR4/MyD88/NF-κB signaling pathway, induce the secretion of various pro-inflammatory cytokines, and result in an inflammatory response in the ovary. [ 6 , 7 ] Chemotherapy causes a large number of neutrophils and macrophages to enter the ovarian tissue, which are distributed mainly in the corpus luteum and atretic follicles, and promotes increased levels of pro-inflammatory factors IL-6, Interleukin-1β (IL-1β), and TNF-α, ultimately inducing an inflammatory response in the ovarian tissue. [ 8 ] In addition, radiation can induce ovarian hypofunction by upregulating the ratio of PPAR-1 mRNA to PPAR-c mRNA in oocytes and ovarian granulosa cells, as well as by downregulating the TGF-β/MAPK signaling pathway and promoting inflammatory responses. [ 9 ] Meanwhile, high-fat and high-sugar diets can stimulate the secretion of ovarian pro-inflammatory cytokines IL-1β, IL-6, and TNF-α by inhibiting the BMP4/Smad9 signaling pathway, decreasing the ratio of helper T cells (CD3+/CD4+) and the ratio of M2 type macrophages (F4/80+/CD206+), and increasing the ratio of activated T cells (CD3+/CD8+) and the ratio of M1 type macrophages (F4/80+/CD68+), causing an imbalance in immune regulation and induction of an inflammatory response in ovarian tissues. [ 10 ] Pro-inflammatory cytokines can also induce an imbalance in the ratio of Helper T-cell 17 (Th17)/regulatory cells and helper T-cell 1 (Th1)/helper T-cell 2 in the ovary and activate monocytes to regulate the immune response, leading to follicular atresia and ovarian failure [ 11 , 12 ] (Fig. 2 ). Inflammation and immune response to POF. POF = premature ovarian failure. Reactive oxygen species (ROS) are byproducts of normal body metabolism and are beneficial to cells and tissues at physiological levels, whereas excess ROS can promote oxidative stress and induce cell apoptosis. [ 13 ] Chemotherapeutic drugs can promote the release of ROS through CYP2E1, inhibit the production of the antioxidant nuclear factor NF-E2-related factor (Nrf2) and heme oxygenase 1 (HO-1), and downregulate the Nrf2/HO-1 signaling pathway, which induces DNA double-strand breaks and oxidative bases in ovarian granulosa cells and decreases the activity of antioxidant enzymes such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) in tissues, causing oxidative stress in ovarian tissues. [ 14 ] Meanwhile, downregulation of Nrf2 also leads to the activation of thioredoxin-interacting protein and NLR family pyrin domain containing 3 inflammatory vesicles, which induce decreased expression of antioxidant enzymes such as glutamate-cysteine ligase catalytic subunit, HO-1, and NAD(P)H quinone dehydrogenase 1, resulting in a significant increase in oxidative stress levels and excessive accumulation of ROS in the ovary, impairing its physiological function. [ 15 ] In addition, chemotherapy can lead to a significant increase in ovarian oxidative stress levels and induce ovarian hypofunction by stimulating the PI3K/Akt/FoxO3a signaling pathway, downregulating the expression levels of SOD and glutathione, and upregulating the expression levels of the pro-oxidant malondialdehyde (MDA) in the ovary [ 16 ] (Fig. 3 ). Effect of oxidative stress on POF. CAT = catalase, GPx = glutathione peroxidase, MDA = malondialdehyde, POF = premature ovarian failure, ROS = reactive oxygen species, SOD = superoxide dismutase. The accumulation of extracellular matrix (ECM) and sustained activation of fibroblast production are the main pathogenic mechanisms of tissue fibrosis. [ 17 ] Transforming growth factor β1 (TGF-β1), an important regulator of fibroblast phenotype and function, promotes the synthesis and deposition of ECM and contributes to the progression of tissue fibrosis. [ 18 ] Chemotherapeutic drugs can upregulate TGF-β1 expression in the ovary by reducing the levels of matrix metalloproteinases (MMPs), which have antifibrotic activity, activate α-smooth muscle actin (α-SMA), inhibit ECM degradation, recruit fibroblast accumulation, and lead to ovarian tissue fibrosis. [ 19 ] In addition, chemotherapeutic agents can induce increased compliance of ovarian tissue Smad2/4 expression by modulating the TGF-β/SMAD axis, leading to tissue fibrosis and ovarian functional impairment. [ 20 ] As an important factor in the development of ovarian tissue fibrosis, connective tissue growth factor (CTGF) interacts with TGF-β1 to regulate the development and progression of tissue fibrosis. Overexpression of TGF-β1 induced CTGF to promote increased collagen production through a paracrine mechanism and accelerated the development of ovarian tissue fibrosis [ 19 ] (Fig. 4 ). Effect of tissue fibrosis on POF. CTGF = connective tissue growth factor, ECM = extracellular matrix, MMPs = matrix metalloproteinases, POF = premature ovarian failure.

Section 3

Vitamin D (VD) is a fat-soluble steroid hormone. The 7-dehydrocholesterol in the skin is irradiated by UV light to produce VD precursors, which are hydroxylated by 27-hydroxylase in the liver to form 25-hydroxy vitamin D 3 [25(OH)D 3 ] and then hydroxylated by 1α-hydroxylase in the kidney tubules to form biologically active 1,25-dihydroxy vitamin D 3 [1,25(OH) 2 D 3 ], which binds to the vitamin D receptor (VDR) in tissues to exert its biological effects and is finally inactivated by 24-hydroxylase and excreted from the body. Recent studies have reported that VD exerts a protective effect on body tissues by inhibiting tissue inflammation, immune response, oxidative stress, and fibrosis progression. VD, an important factor that regulates immune cell function in vitro and in vivo, plays an important role in the antiinflammatory and antiimmune responses. Studies have shown that VDR is a key regulator of innate immune cell differentiation. [ 21 ] Following binding to VDR, 1,25(OH) 2 D 3 activates macrophage antiinflammatory function, antagonizes the activation of NF-κB signaling in T cells, reduces Th1 and Th17 cell production, and upregulates the ratio of Helper T-cell 2 and regulatory cells in tissues. [ 22 – 24 ] VDR can be expressed in dendritic cells, CD4+, CD8 + T cells, and other immune cells, and bind to 1,25(OH) 2 D 3 to maintain a healthy immune system. [ 25 ] VD also slows down the inflammatory response of the body and exerts a suppressive effect on the adaptive immune system by reducing immunoglobulin E expression, inhibiting IκB kinase activity, regulating the NF-κB signaling pathway to upregulate the levels of antiinflammatory cytokines, and downregulating the levels of pro-inflammatory cytokines. [ 26 ] As a stress-activated kinase, P38 mitogen-activated protein kinase increases pro-inflammatory cytokine production and induces inflammatory responses. 1,25(OH) 2 D 3 can upregulate tissue-dephosphorylated MAPK phosphatase 5 levels and inhibit P38 mitogen-activated protein kinase activation to reduce inflammatory cytokine production, thereby decreasing ovarian inflammatory responses. [ 23 ] In addition, 1,25(OH) 2 D 3 binding to VDR in tissues directly inhibits NF-κB binding to the COX-2 promoter, reduces prostaglandin synthesis, decreases the expression of pro-inflammatory factors, such as C-reactive protein, TNF-α, IL-6, and IL-1β, and ultimately ameliorates the inflammatory response and tissue damage [ 27 ] (Fig. 5 ). VD inhibit inflammation and immune response. CRP = C-reactive protein, VD = vitamin D, VDR = vitamin D receptor. VD, a steroid hormone with good antioxidant activity, can reverse high-fat diet-induced oxidative stress by elevating SOD and GPX and reducing MDA concentrations in tissues. [ 28 ] VD can also activate the VD/ Nrf2 signaling pathway in tissues and upregulate the expression of antioxidant factors, such as SOD, CAT, and GPx, to reduce the level of ROS. [ 29 ] Additionally, VDR is an important regulator of cellular mitochondrial respiratory activity. Activated VDR can significantly inhibit cellular mitochondrial respiratory activity, reduce ROS release, and protect tissues from oxidative stress damage. [ 30 ] Meanwhile, it has been shown that VD can effectively reduce total oxidative status, oxidative stress index and MDA levels and increase total antioxidant response and total thiol levels in tissues by inhibiting the activation of NF-κB signaling pathway in tissues, thereby alleviating tissue damage caused by oxidative stress. [ 31 ] In addition, VD can decrease the levels of MDA and total oxidative status, increase the total antioxidant status level in the ovaries, reduce ovarian follicle degeneration and matrix degeneration, and eventually improve ovarian oxidative damage caused by hyperthyroidism [ 32 ] (Fig. 6 ). VD inhibit oxidative stress. VD = vitamin D. The TGF-β signaling pathway has been shown to be one of the major pathways that promote ECM accumulation and exacerbate tissue fibrosis. [ 33 ] VDR, as a negative regulator of fibroblast activation, antagonizes the pro-fibrotic effects of TGF-β1 and has efficient antifibrotic activity, and 1,25(OH) 2 D 3 significantly upregulates VDR levels in tissues, inhibits the pro-fibrotic activity of TGF-β1/α-SMA signaling pathway, and reduces the stimulatory effect of TGF-β1 on fibroblasts and ECM deposition in tissues, thus improving tissue fibrosis. [ 34 ] In addition, it was shown that deficiency of CYP2R1, an important hydroxylase of VD, can lead to tissue fibrosis, while supplementation with VD can upregulate the expression level of CYP2R1 in tissues, inhibit the TGF-β1 signaling pathway, reduce the expression of pro-fibrotic genes collagen type I α 1 and tissue inhibitor of metalloproteinase-1, and elevate the expression of the antifibrotic gene MMPs-2, thus alleviating the development of tissue fibrosis. [ 35 ] Studies have shown that the renin-angiotensin system is one of the important mediators of tissue fibrosis induction, which can regulate the conversion of angiotensin I to angiotensin II and upregulate tissue TGF-β1 expression to induce fibroblast proliferation; in 1,25(OH) 2 D 3 can bind to VDR in tissues and prevent tissue fibrosis formation by inhibiting renin-angiotensin system activation and reducing fibrogenic factor and ECM formation [ 34 ] (Fig. 7 ). VD inhibit tissue fibrosis. RAS = renin-angiotensin system, VD = vitamin D. Experimental studies have shown that VD can promote follicle development and maturation by regulating oxidative stress and steroid production pathways in the ovarian granulosa cells. [ 36 , 37 ] VD plays an important role in the antiinflammatory, immunosuppressive, antioxidant, and antitissue fibrosis aspects of the body. Therefore, VD may interfere with the pathogenesis of POF by suppressing inflammation, immune response, oxidative stress, and tissue fibrosis to improve POF.

Section 4

NETs are extracellular fibers consisting mainly of a meshwork of extracellular DNA, nucleoproteins, and serine proteases released by neutrophils. [ 38 ] Upon initiation of NETosis, neutrophil elastase (NE) and myeloperoxidase degrade the cytoskeleton. Histones are disassembled by peptidylarginine deiminase 4, which allows genomic DNA modified by peptides and proteins to fill the cytoplasm. It is released outside the cell when DNA expansion pressure breaks the cell membrane. At this point, NE, myeloperoxidase, histones, and other proteases are embedded in the DNA backbone, eventually forming NETs outside the neutrophil and becoming a part of the body innate immune system. [ 39 , 40 ] However, excessive deposition of NETs can activate multiple signaling pathways and stimulate cytokine production, leading to inflammatory and immune responses, oxidative stress, and tissue fibrosis. [ 41 ] NETs promote the development of inflammatory responses and are also a source of autoantigens, which are widely involved in the development and progression of inflammatory and autoimmune diseases in the body. NETs activate tissue macrophages and elicit antigen-specific T cell responses, producing pro-inflammatory Th17 and Th1 cells and secreting pro-inflammatory cytokines such as interleukin 17, IL-1β, and TNF-α to induce tissue inflammatory responses and adaptive immune responses. [ 40 , 42 ] In addition, miRNAs from NETs can act on macrophages to downregulate protein kinase C levels and induce excessive TNF-α production in tissues. [ 43 ] In parallel, NETs promote the interaction between NF-κB regulators and IκB kinase to activate the NF-κB signaling pathway, release large amounts of pro-inflammatory cytokines, and induce inflammatory and immune responses in tissues. [ 44 ] In addition, adenylate activated protein kinase (AMPK), a sensor that regulates cellular energy metabolism, has powerful antiinflammatory effects; while excessive release of NETs inhibits AMPK activity and depresses phagocytosis of apoptotic cells by macrophages, as well as exacerbates tissue inflammatory responses by activating the release of the pro-inflammatory mediator high-mobility group box 1, which promotes the secretion of pro-inflammatory factors [ 45 ] (Fig. 8 ). NETs promote inflammation and immune response. HMGB1 = high-mobility group box 1, NETs = neutrophil extracellular trap network, PKC = protein kinase C. NET formation is an important factor in the occurrence of oxidative stress in tissues. When injury and inflammation occur, the body releases chemokines, induces neutrophil recruitment, produces large amounts of ROS, and induces the formation of NETs through the reduced coenzyme II oxidase-ROS-dependent pathway while reducing Nrf2 production, inhibiting the AMPK/Nrf2 signaling pathway, depressing SOD and CAT activity in tissues, and inducing the development of oxidative stress in tissues. [ 46 , 47 ] It has been shown that nanoalumina can induce excessive formation of NETs, further inhibit the activities of SOD, CAT, and glutathione, upregulate the expression levels of inducible nitric oxide synthase, caspase-1, and caspase-11, and exacerbate tissue oxidative stress damage. [ 48 ] Sirtuin 3 has been shown to be a mitochondria-dependent deacetylase that protects tissues from oxidative stress damage. In contrast, excessive NET formation can induce NET-mediated oxidative stress damage in tissues by inhibiting Sirtuin 3 activity and reducing SOD2 transcription in tissues [ 49 ] (Fig. 9 ). NETs promote oxidative stress. iNOS = inducible nitric oxide synthase, NETs = neutrophil extracellular trap network. NETs can promote fibrotic processes in various tissues, such as the liver and skeletal muscles. [ 50 , 51 ] When tissue is injured, a large number of neutrophils are recruited to the site of injury, inducing NETosis, which produces NETs that stimulate cells to create urokinase-type plasminogen activator, release TGF-β1 enclosed in the ECM, activate the TGF-β1/α-SMA signaling pathway, and downregulate the level of MMPs, promoting collagen production and ECM deposition in tissues, leading to tissue fibrosis. [ 52 ] NE is an important component of NETs. Studies have shown that NE not only activates TGF-β and induces ECM deposition but also directly enters fibroblasts, promoting their proliferation and differentiation capacity, ultimately leading to tissue fibrosis. [ 53 ] In addition, NETs can also promote fibroblast proliferation and migration and induce the conversion of fibroblasts to myofibroblast phenotype by upregulating the expression of CTGF, promoting collagen production, and ultimately aggravating tissue fibrosis [ 54 ] (Fig. 10 ). NETs promote oxidative stress. CTGE = connective tissue growth factor, NE = neutrophil elastase, NETs = neutrophil extracellular trap network. The development of POF is dependent on the involvement of inflammation and immune response, oxidative stress, and tissue fibrosis, whereas the excessive formation of NETs may exacerbate inflammation and immune response, oxidative stress, and fibrosis in the organism. Therefore, we speculated that excessive NET formation may drive the pathological development of POF.

Section 5

Long-term administration of low-dose VD has been reported to significantly inhibit NET formation in tissues, which in turn upregulates vascular endothelial growth factor expression and reduces the production of pro-inflammatory cytokines, thereby improving tissue microvascular growth and alleviating the inflammatory response. [ 55 ] Therefore, we hypothesized that VD may improve POF by inhibiting NET formation and attenuating inflammation, immune response, oxidative stress, and fibrosis in ovarian tissues. Follicular atresia is the main pathological change in POF and is closely related to inflammatory responses and autoimmune abnormalities. [ 56 ] Both VD and NETs regulate the NF-κB signaling pathway and antigen-specific T cell responses. Thus, it is hypothesized that POF patients may be treated with appropriate VD supplementation to inhibit NET formation, improve the tolerance of ovarian tissue to autoimmunity, and alleviate ovarian inflammation and immune response. Excessive ROS production in the body has been shown to be associated with inhibition of follicular development and damage to ovarian granulosa cells in mammals. NETs inhibit Nrf2 production and induce tissue oxidative stress, whereas VD regulates cellular mitochondrial respiratory activity and reduces tissue ROS levels. Therefore, VD may regulate the VD/Nrf2 signaling pathway by binding to VDR in the ovarian epithelium, inhibiting the formation of NETs, reducing ROS production, and upregulating the level of antioxidant enzymes to alleviate oxidative stress-induced decline in ovarian function. Furthermore, TGF-β1 promotes ECM deposition and ovarian fibrosis by activating the fibrosis-related gene α-SMA in ovarian tissues. NETs promote tissue TGF-β1 production, whereas VD downregulates the TGF-β1/α-SMA pathway to inhibit tissue fibrosis. Therefore, we propose the hypothesis that VD may reduce ECM deposition in ovarian tissue by inhibiting the formation of NETs and downregulating the TGF-β1/α-SMA signaling pathway, thereby alleviating ovarian fibrosis and improving ovarian function (Fig. 11 ). VD may interfere with POF by inhibiting the production of NETs, to modulate the said pathways and targets, suppressing ovarian tissue inflammation and immune responses, oxidative stress, as well as tissue fibrosis. NETs = neutrophil extracellular trap network, POF = premature ovarian failure, VD = vitamin D.

Section 6

However, the pathogenesis of POF remains unclear. Therefore, it is one of the most important hotspots for further investigation of new targets for the treatment of POF and the development of highly effective drugs with no significant adverse reactions for the prevention and treatment of POF. NETs have become key targets for the development of pathological changes and clinical treatment of various diseases and are closely related to various inflammatory and autoimmune diseases. VD may interfere with POF by regulating ovarian granulosa cell apoptosis and tissue inflammatory responses. VD may play an important role in POF by inhibiting the formation of NETs, including inflammatory response, immune response, oxidative stress, and tissue fibrosis; however, the exact mechanism is still unclear. In the future, we can carry out high-quality research in vitro, in vivo, and in clinical treatment, hoping to provide new directions and new ideas for the clinical treatment of POF, and to provide a theoretical basis and scientific support for the development of emerging targeted drugs for POF.

Intro

Premature ovarian failure (POF) is a disease of the female reproductive system characterized by a decrease in the development of mature follicles in the ovaries and an increase in atretic follicles as the main pathological change. [ 1 ] The morbidity of POF is increasing in young women as people lifestyles and dietary structures change. According to relevant data, approximately 45 million women in China have been diagnosed with POF, and the prevalence rate has reached 1/10,000, 1/1000, and 1/100 in women aged 20 seconds, 30 seconds, and 40 seconds, respectively. [ 2 ] The disease not only seriously affects women physical and mental health but also imposes a huge burden on families and society. [ 3 ] Currently, estrogen and progestin replacement, ovulation promotion, and immunotherapy are commonly used to treat POF, but they cannot alter the pathological nature of reduced mature follicle development. The pathogenesis of POF is unclear, but the most recent research demonstrates that tissue fibrosis, oxidative stress, immunological response, and inflammation are significant contributors to the pathogenesis of POF, while excessive deposition of neutrophil extracellular traps (NETs) can promote the release of cytokines, which can harm tissue function by causing inflammation, immunology, oxidative stress, and fibrosis. Interestingly, investigations have discovered that VD can inhibit the formation of NETs in tissues, and can promote follicle development and maturation by regulating oxidative stress and steroid production pathways in the ovarian granulosa cells. Therefore, we propose the scientific hypothesis that VD may prevent POF by inhibiting NET formation and further explore its potential mechanism, with the aim of providing new ideas for the clinical treatment of POF (Fig. 1 ). Regulation mechanism of vitamin D on POF through inhibition of NETs. NETs = neutrophil extracellular trap network, POF = premature ovarian failure.

Author

Conceptualization: Menglu Chen, Lailai Li, Yunzhi Chen. Data curation: Menglu Chen, Yihui Chai, Yuqi Yang, Sibu Ma. Funding acquisition: Lailai Li. Validation: Xiang Pu. Visualization: Yihui Chai, Yuqi Yang. Writing – original draft: Menglu Chen. Writing – review & editing: Lailai Li, Xiang Pu, Yunzhi Chen.

Acknowledgments

We thank Yihui Chai and Yuqi Yang for assistance in data collection and organization and Sibu Ma for his help with data analysis.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: pmc-nxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

MeSH descriptors

Extracellular Traps Menopause, Premature Primary Ovarian Insufficiency Primary Ovarian Insufficiency Female Humans Neutrophils Neutrophils Vitamin D Vitamin D Vitamin D Vitamins Vitamins Vitamins

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

Cited by (2)

References (60)

Cited by (2)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:39:18.785821+00:00
License: CC0 · commercial use OK